Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

依乐韦 - NMPA Drug Approval Details

Approvals/NMPA/Zanamivir Powder for Inhalation

Approved

化学药品

Zanamivir Powder for Inhalation

LABORATOIRE GLAXOSMITHKLINE🇨🇳 National Medical Products Administration

Approval Date: Apr 20, 2022
Approval ID: 8H1Or8shs6m
Company: LABORATOIRE GLAXOSMITHKLINE
Type: 化学药品

Approval Details

Approval Id: 8H1Or8shs6m
Approval Number: 国药准字HJ20140462
Generic Name: 扎那米韦吸入粉雾剂
Generic Name En: Zanamivir Powder for Inhalation
Trade Name: 依乐韦
Drug Type: 化学药品
Dosage Form: 吸入粉雾剂
Strength: 5mg（以C₁₂H₂₀N₄O₇计）
Reg Date: 2022-04-20
Expired Date: 2027-04-19
Company Name: LABORATOIRE GLAXOSMITHKLINE
Production Company Name: GLAXO WELLCOME PRODUCTION
Company Detail Path: /organization/laboratoire-glaxosmithkline
Production Company Detail Path: /organization/glaxo-wellcome-production

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Apr 20, 2022

Approval ID

8H1Or8shs6m

Type

化学药品

Back to NMPA Approvals